Psoriasis is a chronic, multifactorial, inflammatory disorder, with an estimated prevalence of 0.71% in children....
Leggi tuttoInvestigators have found no evidence of an increased risk of venous thromboembolic events (VTE) in patients treated with tofacitinib for rheumatoid arthritis (RA), psoriasis (PsO), psoriatic arthritis (PsA), or ulcerative colitis (UC)...
Leggi tuttoPatients with active psoriatic arthritis and plaque psoriasis showed resolution of skin lesions within 3 weeks, as indicated by achieving Psoriasis Area and Severity Index (PASI 75) and PASI 90 with tofacitinib...
Leggi tuttoPubblicato il report della riunione mensile del Comitato per i medicinali ad uso umano dell'Agenzia del farmaco europea. Tra gli otto nuovi prodotti raccomandati per l'immissione in commercio anche due biosimilari e due farmaci generic...
Leggi tuttoTofacitinib demonstrated superior efficacy versus placebo in the treatment of active psoriatic arthritis (PsA) that has previously not responded well to treatment....
Leggi tuttoResearchers have successfully treated patients with moderate to severe eczema using a rheumatoid arthritis drug recently shown to reverse 2 other disfiguring skin conditions: vitiligo and alopecia areata...
Leggi tutto